• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Women’s Health Platform Maven Clinic Scores $90M in Funding

Share:

November 22, 2022

Cropped shot of an attractive young businesswoman standing alone in her office and working on a tablet

Virtual women and family health provider Maven Clinic announced it raised $90 million in a Series E funding round, bringing the virtual clinic’s funding total to $300 million.

General Catalyst led the round with participation from La Famiglia, CVS Health Ventures, and Intermountain Ventures. Existing investors also participated, including Oak HC/FT, Dragoneer Investment Group, Sequoia, Lux Capital and Icon Ventures.

WHAT IT DOES

The digital reproductive health and family platform focuses on a woman’s health journey from fertility to menopause. The company claims to host 15 million members, a 5x increase since it gained unicorn status with its $110 million Series D funding round in 2021.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

WHAT IT’S FOR

The funds will support the technology-enabled women’s health clinic and benefits platform in improving personalization across its offerings for commercial and Medicaid populations and help to expand its global offerings.

“We have reimagined the care model to address the complex needs of women and families in a global system that was not designed for them,” Kate Ryder, founder and CEO of Maven Clinic, said in a statement.

“Whether it’s a pregnant woman faced with access issues in rural America, working parents in India needing financial support and navigation for infertility treatment, a same-sex couple facing bias in the opaque surrogacy industry, or a senior executive unable to get support for menopause, our platform shows up reliably, affordably, and relentlessly focused on patient outcomes.”

MARKET SNAPSHOT

Since the Supreme Court’s decision to overturn Roe v. Wade, there’s been a spotlight on women’s health, and in a year where funding has slowed, Maven has shown to endure.

According to a report by Silicon Valley Bank published earlier this month, health tech companies in the U.S. and European Union raised about $23 billion this year, a sharp downward shift from the massive investments made in 2021.

The report tallied funding through Sept. 30 of this year, noting a particularly sharp decline in the third quarter, dropping 39% from Q2 and 67% from the height of investment seen in the second quarter last year.

Still, there was a growth in female-founded health tech companies, with women’s health startups raising $877 million in 2022. Fertility and pregnancy care were a considerable part of the women’s health market, making up 68% of the investment.
Source: Mobile Health News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Humana, Fresenius Medical Care Expand Partnership to Improve Care Coordination for Medicare Advantage MembersHumana, Fresenius Medical Care Expand Partnership to Improve Care Coordination for Medicare Advantage Members
  • Healthcare task force calls for AI policies to align with real-world workflowHealthcare task force calls for AI policies to align with real-world workflow
  • Headlight Mental Health Scores $18M to Expand Teletherapy, In-Person CareHeadlight Mental Health Scores $18M to Expand Teletherapy, In-Person Care
  • Are EHRs A Guard Against Human Nature?Are EHRs A Guard Against Human Nature?
  • Mission Bio Lands $70M to Expand Cancer Therapies With Single-Cell Multi-Omics PlatformMission Bio Lands $70M to Expand Cancer Therapies With Single-Cell Multi-Omics Platform
  • Fujifilm Sonosite Unveils Next-Gen Point-of-Care Ultrasound System for Frontline Clinicians
  • Longfellow Acquires Palo Alto Technology Center from KBS for $205 MillionLongfellow Acquires Palo Alto Technology Center from KBS for $205 Million
  • Validant Acquires DataRevive, a Regulatory Strategy and Consulting Business Focused on Novel Therapeutics and BiologicsValidant Acquires DataRevive, a Regulatory Strategy and Consulting Business Focused on Novel Therapeutics and Biologics

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications